Retatrutide: a triple incretin receptor agonist for obesity management
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management. AREAS COVERED: Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side effects. The role of glucagon receptor agonism in the management of heart failure and its potential impact on eating patterns have also been covered in this article. EXPERT OPINION: Although the reductions in HbA1c and dose-dependent weight loss among individuals with T2DM were significantly more for higher doses of retatrutide, it needs to be observed that the active comparator was dulaglutide, which is not approved for the treatment of obesity, at a dose of 1.5 mg, which is much lower than the highest approved dose of 4.5 mg. Dose-dependent increase in heart rate and incidents of mild to moderate cardiac arrythmias raise cardiovascular safety concerns and signify that carrying out long-term cardiovascular outcome trials (CVOTs) will be critical. In addition, retatrutide's potential in heart failure management is intriguing given the series of positive findings of semaglutide on cardiovascular outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has a dose-dependent action and causes a decrease in gastric emptying, while with a half-life of 6 days, it can mostly be used on a weekly basis.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [36]
In the citing paper
“Retatrutide shows mostly hepatic metabolism but does not interact with cytochrome P450 enzymes [36].”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [36]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“These agents act on one or more G protein-coupled receptors including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors affecting various neuroendocrine mechanisms associated with obesity [4–8].”
BackgroundTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
American Society of Anesthesiologists
Marx, G. F. (1982) · Obstetric Anesthesia Digest · doi:10.1097/00132582-198203000-00028 · Cited by 1,899
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“…symptoms, physical limitations, and exercise function among patients with heart failure with pre-served ejection fraction in the STEP-HFpEF trial [50], there is a growing interest to understand if the increasing portfolio of obesity medicines could be beneficial in the management of heart…”
BackgroundRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 2×
“Recently, retatrutide, a triple agonist of GLP-1-GIP-GCG receptor, showed positive results for obesity management in a phase-2 trial [11].”
BackgroundWadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738 · cited 1×
“With the approval of semaglutide (Wegovy) and the promising results from phase 3 trials of tirzepatide [1,2], the treat-ment landscape of obesity is a rapidly evolving one [3].”
BackgroundThe essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · cited 1×
“It has shown to decrease weight significantly in both normal weight individuals and people living with overweight in trials without hampering glucose tolerance [26,27], and this encouraged consideration of glucagon receptor agonism for body weight reduction.”
BackgroundRosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01053-x · Cited by 423
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense
Horton, J. L., Davidson, M. T., Kurishima, C., Vega, R. B., Powers, J. C., Matsuura, T. R., Petucci, C., Lewandowski, E. D., Crawford, P. A., Muoio, D. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124079 · Cited by 364
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363 · cited 1×
“It has shown to decrease weight significantly in both normal weight individuals and people living with overweight in trials without hampering glucose tolerance [26,27], and this encouraged consideration of glucagon receptor agonism for body weight reduction.”
BackgroundFrias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01163-7 · Cited by 334 · cited 1×
“A phase-2 trial reported a combination of semaglutide with a long-acting amylin analogue cagrilintide resulting in significantly greater loss in weight compared to semaglutide alone among adults with T2DM with a BMI of 27 kg/m 2 or higher and on metformin [33].”
BackgroundGlucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299 · cited 1×
“These agents act on one or more G protein-coupled receptors including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors affecting various neuroendocrine mechanisms associated with obesity [4–8].”
BackgroundTan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
Gerich, J. E., Lorenzi, M., Schneider, V., Karam, J. H., Rivier, J., Guillemin, R., & Forsham, P. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197409122911102 · Cited by 239
Incretin hormones and the satiation signal
Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 188
Effect of Glucagon on Food Intake and Body Weight in Man
Schulman, J. L., Carleton, J. L., Whitney, G., & Whitehorn, J. C. (1957) · Journal of Applied Physiology · doi:10.1152/jappl.1957.11.3.419 · Cited by 174
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12585 · Cited by 167
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
Lorenz, M., Lawson, F., Owens, D., Raccah, D., Roy-Duval, C., Lehmann, A., Perfetti, R., & Blonde, L. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0490-6 · Cited by 166
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152 · cited 1×
“Nevertheless, triple agonists have outperformed both GLP-1RAs and GLP-1:GIP co-agonist for providing weight reduction in pre-clinical research [32], which definitely strengthens the hope for this novel class.”
BackgroundUrva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14110 · Cited by 143 · cited 1×
“In humans, the greatest GE effect happened after the initial dose of retatrutide, and the maximum extent was similar to previously seen for tirzepatide [41].”
ResultMaselli, D., Atieh, J., Clark, M. M., Eckert, D., Taylor, A., Carlson, P., Burton, D. D., Busciglio, I., Harmsen, W. S., Vella, A., et al. (2022) · Obesity · doi:10.1002/oby.23481 · Cited by 136 · cited 1×
“The magnitude of GE delay diminished at days 30 and 79, which is similar to previous reports on liraglutide usage at 16 weeks compared to 5 weeks since initiation [42].”
ResultControl of body weight: a physiologic and transgenic perspective
Frühbeck, G., & Gómez‐Ambrosi, J. (2003) · Diabetologia · doi:10.1007/s00125-003-1053-4 · Cited by 125
Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity · doi:10.1002/oby.23673 · Cited by 124 · cited 1×
“The STEP-5 trial showed sema-glutide to have a significant impact on 2–year eating control associated with reduction in weight [47].”
MethodGerich, J. E., Lorenzi, M., Schneider, V., Kwan, C. W., Karam, J. H., Guillemin, R., & Forsham, P. H. (1974) · Diabetes · doi:10.2337/diab.23.11.876 · Cited by 103
Karwi, Q. G., Zhang, L., Wagg, C. S., Wang, W., Ghandi, M., Thai, D. L., Yan, H., Ussher, J. R., Oudit, G. Y., & Lopaschuk, G. D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0806-4 · Cited by 94
Insulin and Glucagon: Partners for Life
Holst, J. J., Holland, W., Gromada, J., Lee, Y., Unger, R. H., Yan, H., Sloop, K. W., Kieffer, T. J., Damond, N., & Herrera, P. L. (2017) · Endocrinology · doi:10.1210/en.2016-1748 · Cited by 90
Jalleh, R. J., Jones, K. L., Rayner, C. K., Marathe, C. S., Wu, T., & Horowitz, M. (2022) · Diabetologia · doi:10.1007/s00125-022-05796-1 · Cited by 87 · cited 1×
“Focusing on such life-threatening adverse events and understanding their potential long-term impact is critical in designing future roadmaps of retatrutide and other such triple agonists in the pipeline, especially since long-standing T2DM is commonly associated with underlying gastroparesis [44].”
BackgroundMetabolic effects of glucagon in the Wistar rat
SALTER, J. M. (1960) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/8.5.535 · Cited by 85 · cited 1×
“Salter demonstrated that glucagon leads to an increase in energy expenditure in small animals [23].”
BackgroundBlockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
Damond, N., Thorel, F., Moyers, J. S., Charron, M. J., Vuguin, P. M., Powers, A. C., & Herrera, P. L. (2016) · eLife · doi:10.7554/elife.13828 · Cited by 74
Li, A., Lian, L., Chen, X.-N., Cai, W.-H., Fan, X., Fan, Y.-J., Li, T., Xie, Y., & Zhang, J. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.08.009 · Cited by 74
The role of glucagon in the regulation of plasma lipids
Schade, D. S., Woodside, W. F., & Eaton, R. P. (1979) · Metabolism · doi:10.1016/0026-0495(79)90215-4 · Cited by 71
Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity · doi:10.1002/oby.23725 · Cited by 69 · cited 1×
“Expensive anti-obesity medicines will be out of reach for majority in LMICs where more than half, and oftentimes up to 90%, of expenses on medicines are out-of-pocket [37].”
BackgroundThe role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus
Sakurai, H., Dobbs, R. E., & Unger, R. H. (1975) · Metabolism · doi:10.1016/0026-0495(75)90067-0 · Cited by 62
Nicolau, J., Pujol, A., Tofé, S., Bonet, A., & Gil, A. (2022) · Physiology & Behavior · doi:10.1016/j.physbeh.2022.113967 · Cited by 54
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents
Geisler, C. E., Antonellis, M. P., Trumbauer, W., Martin, J. A., Coskun, T., Samms, R. J., & Hayes, M. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14843 · Cited by 51
SGLT2 inhibition and glucagon secretion in humans
Saponaro, C., Pattou, F., & Bonner, C. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.06.005 · Cited by 49
Glucagon infusion in normal man: Effects on 3-mthylhistidine excretion and plasma amino acids
Fitzpatrick, G. F., Meguid, M. M., Gitlitz, P. H., & Brennan, M. F. (1977) · Metabolism · doi:10.1016/0026-0495(77)90091-9 · Cited by 41
van Ruiten, C. C., ten Kulve, J. S., van Bloemendaal, L., Nieuwdorp, M., Veltman, D. J., & IJzerman, R. G. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105667 · Cited by 31
Neumann, U. H., Ho, J. S. S., Mojibian, M., Covey, S. D., Charron, M. J., & Kieffer, T. J. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.014 · Cited by 29
SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy
Anker, S. D., Usman, M., & Butler, J. (2022) · Circulation · doi:10.1161/circulationaha.122.060348 · Cited by 29
Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure
Gao, C., Ren, S. V., Yu, J., Baal, U., Thai, D., Lu, J., Zeng, C., Yan, H., & Wang, Y. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.11.001 · Cited by 28
The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying
Urva, S., O'Farrell, L., Du, Y., Loh, M. T., Hemmingway, A., Qu, H., Alsina‐Fernandez, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15167 · Cited by 28 · cited 1×
“Urva et al. reported retatrutide to cause delayed GE in both mice and humans [40].”
BackgroundAranda, R., Orenes‐Piñero, E., Arribas, J. M., Cánovas-López, S., & Hernández-Cascales, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01859-8 · Cited by 23
Effect of the secretin family of peptides on gastric emptying and small intestinal transit in rats
Murthy, S. N. S., & Ganiban, G. (1988) · Peptides · doi:10.1016/0196-9781(88)90168-4 · Cited by 19
Shifting Tides Offer New Hope For Obesity
Rosen, C. J., & Ingelfinger, J. R. (2022) · New England Journal of Medicine · doi:10.1056/nejme2206939 · Cited by 17
Role of the Gut Microbiota in Glucose Metabolism During Heart Failure
Bao, P., Zhang, Z., Liang, Y., Yu, Z., Xiao, Z., Wang, Y., Yu, Y., Liu, W., Chen, X., Huang, Z., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903316 · Cited by 9
Lindsay, R. T., Ambery, P., Jermutus, L., & Murray, A. J. (2023) · Physiological Reports · doi:10.14814/phy2.15597 · Cited by 5
Research works printed but not linked: 1
- Collip JB. Delayed manifestation of the physiological effects of insulin following the administration of certain pancreatic extracts. Am J Physiol. 1923;63(3):391–392.
Cited by
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025) · Biomolecules · doi:10.3390/biom15060796 · Cited by 29
“Retatrutide shows mostly hepatic metabolism but does not interact with cytochrome P450 enzymes [36].”
The power of three: Retatrutide’s role in modern obesity and diabetes therapy
Abdul-Rahman, T., Roy, P., Ahmed, F. K., Mueller-Gomez, J. L., Sarkar, S., Garg, N., Femi-Lawal, V. O., Wireko, A. A., Thaalibi, H. I., Hashmi, M. U., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177095 · Cited by 27
Windram, M., Lovelock, D. F., Carew, J. M., Krieman, C. G., Hendershot, C. S., & Besheer, J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06854-3 · Cited by 8
The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
Shestakova, M. V., & Bashlykova, R. O. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.10.203366 · Cited by 6
Liedtke, W. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5118371 · Cited by 2
Metadata
- Authors
- Ray, A.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Ray, Avik
- ORCID
- Ray, Avik
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2023-10-31
- Volume
- 32
- Issue
- 11
- Pages
- 1003-1008
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W4388023373
- Cited by
- 11
- References
- 55
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 2
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- funding from any source
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- retatrutide, obesity treatment, type 2 diabetes, weight loss, HbA1c, heart failure, cardiovascular safety, cardiac arrhythmias, dulaglutide, semaglutide, gastrointestinal adverse effects
- MeSH terms
- Obesity Management, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Heart Failure, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.